Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD

BACKGROUND: Phase III studies demonstrated efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY) in subjects with COPD. Secondary analyses were performed to examine the effect of background long-acting beta(2)-agonist (LABA) use on the efficacy and safety of nebulized GLY. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerwin, Edward M, Tosiello, Robert, Price, Barry, Sanjar, Shahin, Goodin, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157543/
https://www.ncbi.nlm.nih.gov/pubmed/30275690
http://dx.doi.org/10.2147/COPD.S172408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157543/
https://www.ncbi.nlm.nih.gov/pubmed/30275690
http://dx.doi.org/10.2147/COPD.S172408

Ejemplares similares